FDA — authorised 14 December 2012
- Application: NDA200677
- Marketing authorisation holder: RECORDATI RARE
- Local brand name: SIGNIFOR
- Indication: SOLUTION — SUBCUTANEOUS
- Status: approved
🇺🇸 Signifor (pasireotide) in United States
FDA authorised Signifor (pasireotide) on 14 December 2012
Marketing authorisation
Signifor (pasireotide) in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Endocrinology approved in United States
Frequently asked questions
Is Signifor (pasireotide) approved in United States?
Yes. FDA authorised it on 14 December 2012.
Who is the marketing authorisation holder for Signifor (pasireotide) in United States?
RECORDATI RARE holds the US marketing authorisation.